quantisnow
FeedTopReportsPricing
⌘K
Live feed
00:15:16·158d
SECFiling
ESSA Pharma Inc. logo

SEC Form EFFECT filed by ESSA Pharma Inc.

EPIX· ESSA Pharma Inc.
Health Care
Original source

Companies

  • EPIX
    ESSA Pharma Inc.
    Health Care

Recent analyst ratings

  • Nov 4UpdateJefferies-
  • Nov 4UpdateOppenheimer-
  • Nov 4UpdatePiper Sandler$2.00
  • Jun 26UpdateOppenheimer$17.00
  • Aug 17UpdateOppenheimer$22.00

Related

  • SEC160d
    Amendment: SEC Form SCHEDULE 13G/A filed by ESSA Pharma Inc.
  • SEC160d
    Amendment: SEC Form SCHEDULE 13G/A filed by ESSA Pharma Inc.
  • SEC178d
    SEC Form 15-12G filed by ESSA Pharma Inc.
  • INSIDER190d
    President and CEO Parkinson David Ross returned 65,675 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER190d
    Chief Financial Officer Wood David S. returned 33,343 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER190d
    Director Berger Franklin M returned 784,404 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER190d
    Director Glickman Richard M returned 43,240 shares to the company, closing all direct ownership in the company (SEC Form 4)
  • INSIDER190d
    Director Requadt Scott returned 30,002 shares to the company, closing all direct ownership in the company (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022